CLIONA ROONEY to Bone Marrow Transplantation
This is a "connection" page, showing publications CLIONA ROONEY has written about Bone Marrow Transplantation.
Connection Strength
1.553
-
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
Score: 0.150
-
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6.
Score: 0.130
-
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
Score: 0.127
-
Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
Score: 0.110
-
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
Score: 0.108
-
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
Score: 0.100
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.098
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.098
-
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
Score: 0.096
-
Epstein-Barr infection after bone marrow transplantation. Blood. 1994 Mar 15; 83(6):1706-8.
Score: 0.093
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.092
-
Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
Score: 0.053
-
Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
Score: 0.040
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.036
-
Cytotoxic T cells and immunotherapy. Pediatr Radiol. 1998 Jul; 28(7):489-91.
Score: 0.031
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.030
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.030
-
Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
Score: 0.026
-
Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
Score: 0.026
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.023
-
Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
Score: 0.023
-
Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
Score: 0.022
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.009